Customize your JAMA Network experience by selecting one or more topics from the list below.
Since Majendie,1 in 1846, first found an amylolytic enzyme in human blood, and later, in 1863, Cohnheim2 wrote of its presence in the urine, Plósz and Tiegil,3 Foster,4 Lépine5 and many other writers have confirmed these earlier investigators and attempted to determine the quantitative value of amylase with reference to certain pathological conditions, more particularly those of the kidney. All the various methods devised were unwieldy and inaccurate however, and most of the information gained contradictory. In 1908 Wohlgemuth6 devised a quantitative test which for the simplicity, accuracy and uniformity of its results so far surpassed any test previously proposed that it has been generally adopted by chemists and clinicians alike for the estimation of amylase in blood, urine, feces and other body substances.
Nearly all the contributions to our literature on this subject have come from French and German writers, and
GEYELIN HR. A CLINICAL STUDY OF AMYLASE IN THE URINE: WITH ESPECIAL REFERENCE TO THE PHENOLSULPHONEPHTHALEIN TEST†. Arch Intern Med (Chic). 1914;XIII(1):96–120. doi:10.1001/archinte.1914.00070070101005
Create a personal account or sign in to: